Opexa Therapeutics, Inc.
| Nasdaq: OPXA
Opexa Therapeutics, Inc. is a biopharmaceutical company developing personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis. This therapy is based on T-cell technology. The company's therapy candidate, Tcelna, is a personalized T-cell immunotherapy for the treatment of secondary progressive multiple sclerosis. The company was founded in 2004 and is headquartered in The Woodlands, TX.